NYU Study: Blood Tests Detect Lung Cancer Recurrence Before Imaging

Blood Test Detects Lung Cancer Relapse Months Before Scans Show Growth

A specialized blood test can detect early-stage lung cancer recurrence a median of 16.7 months before conventional imaging spots the disease, according to a study published in the Journal of Molecular Diagnostics and widely discussed on October 23, 2026. Researchers at NYU Langone Health evaluated 42 patients treated for stage IA non-small cell lung cancer, tracking circulating tumor DNA (ctDNA) to catch microscopic signs of relapse long before clinical symptoms or standard scans reveal them.

While the findings offer a glimpse into the future of cancer surveillance, the test is not yet a standard part of routine medical care. The study highlights both the promise of liquid biopsies and the significant clinical questions that remain unanswered regarding patient survival benefits.

How NYU Langone Researchers Tracked Circulating Tumor DNA

The research team at NYU Langone Health followed 42 individuals who underwent surgery for stage IA non-small cell lung cancer, which represents the earliest stage of the disease with the smallest tumor sizes. Investigators sequenced each patient’s removed tumor to map its unique genetic fingerprint. They then screened serial blood samples collected over time for that exact genetic signature, a method commonly referred to as a liquid biopsy.

Out of the 12 patients in the cohort whose cancer eventually returned, the blood test successfully identified the recurrence in nine of them, yielding a sensitivity of 75%. For patients whose cancer did not return, the test maintained a correct negative result approximately 83% to 89% of the time. Beyond predicting standard relapses, the test also helped clinicians differentiate true recurrences from entirely new, unrelated second primary lung tumors in complex cases where standard pathology proved ambiguous.

Current Limitations and What the Data Does Not Prove

Detecting a cancer recurrence earlier does not automatically equate to living longer. The study did not demonstrate that intervening upon a positive ctDNA blood test improves overall survival rates. Because the study involved a small patient cohort and a retrospective design, and because several authors maintain affiliations with the commercial developer of the sequencing platform, the findings serve as an early warning signal rather than a new standard of care.

A larger systematic review and meta-analysis published in late 2025 across 13 studies and 1,309 non-small cell lung cancer patients established that detectable ctDNA immediately following surgery correlates with a substantially higher risk of relapse, showing a hazard ratio of 6.41. Repeated testing over time showed an even stronger association, with a hazard ratio of 8.70. However, researchers still need prospective clinical trials to prove that acting on these early molecular signals actually improves patient longevity and quality of life.

Standard Post-Operative Monitoring and Questions for Oncologists

Current post-treatment monitoring relies heavily on physical examinations, scheduled imaging like computed tomography (CT) scans, and standard laboratory panels. The American Cancer Society recommends that asymptomatic patients undergo checkups roughly every three months for the first two years, every six months for several more years, and at least annually starting from the fifth year, though exact schedules fluctuate based on individual clinical risk factors.

Patients managing post-surgical follow-up care can discuss several targeted inquiries with their oncology teams:

• Is a ctDNA assay available for my specific case, and is it part of a clinical trial or standard clinical service?
• What specific treatment adjustments would we make if the test returned positive versus negative?
• Does the assay require a preserved sample of my original tumor, and what is the turnaround time for results?
• How is the test billed, and will my scheduled imaging and physical exams continue as planned?

Frequently Asked Questions About Liquid Biopsies and Lung Cancer Recurrence

Can a standard blood test catch lung cancer coming back?

Routine chemistry panels and general blood tests cannot reliably detect a recurrence on their own. Specialized ctDNA assays can find trace genetic fragments shed by residual cancer cells, but these tests are still undergoing clinical evaluation and remain outside standard follow-up protocols.

Does a negative ctDNA result guarantee I am cancer-free?

No negative test provides absolute certainty. In the NYU Langone Health study, approximately 25% of the recurrences were missed by the blood test, meaning clinicians must always interpret negative liquid biopsy results alongside physical exams and scheduled CT scans.

How often does early-stage lung cancer return after surgery?

Recurrence rates depend closely on the initial tumor stage and type of cancer. Even individuals treated for stage IA disease face some risk of relapse, which makes adherence to a structured surveillance schedule critical.

More on Lung Cancer: Lung Cancer Radiotherapy: New Study Data and European Guidelines